These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8948925)

  • 1. [Clinical trial with tibolone in postmenopausal replacement therapy].
    Zarate A; Hernandez M; Ochoa R; Santos A
    Ginecol Obstet Mex; 1996 Jan; 64():47-50. PubMed ID: 8948925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sexual dysfunction in the peri- and postmenopause. Status of incidence, pharmacological treatment and possible risks. A secondary publication.
    Gregersen N; Jensen PT; Giraldi AE
    Dan Med Bull; 2006 Aug; 53(3):349-53. PubMed ID: 17092454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women.
    Osmanağaoğlu MA; Atasaral T; Baltaci D; Bozkaya H
    Climacteric; 2006 Dec; 9(6):464-72. PubMed ID: 17085380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [What's new in hormone replacement therapy for postmenopausal women? I. Advantages of hormone replacement therapy (HRT)].
    Martin-Du Pan RC; Luzuy F
    Rev Med Suisse Romande; 2000 Jun; 120(6):515-21. PubMed ID: 11014096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy.
    Wu MH; Pan HA; Wang ST; Hsu CC; Chang FM; Huang KE
    Climacteric; 2001 Dec; 4(4):314-9. PubMed ID: 11770188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
    Diaby V; Perreault S; Lachaine J
    Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women.
    Sezer Ozer K; Erenus M; Yoldemir T
    Climacteric; 2009 Feb; 12(1):66-71. PubMed ID: 19012050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
    Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up.
    Prelevic GM; Markou A; Arnold A; Bartram C; Puzigaca Z; Ginsburg J
    Maturitas; 2004 Mar; 47(3):229-34. PubMed ID: 15036493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tibolone and the promise of ideal hormone-replacement therapy.
    El-Hajj Fuleihan G
    N Engl J Med; 2008 Aug; 359(7):753-5. PubMed ID: 18703480
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
    Bjarnason NH
    Dan Med Bull; 2005 May; 52(2):64-81. PubMed ID: 16009050
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic features of menopausal and postmenopausal applicants for life insurance.
    Schiefeling M
    J Insur Med; 1996; 28(1):27-34. PubMed ID: 10172866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
    Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
    Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tibolone therapy in postmenopausal women with a history of many risk factors].
    Szántó F
    Orv Hetil; 2003 Apr; 144(15):701-4. PubMed ID: 12774429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B.
    Castelo-Branco C; Casals E; Figueras F; Sanjuan A; Vicente JJ; Balasch J; Vanrell JA
    Menopause; 1999; 6(2):92-7. PubMed ID: 10374214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.